Your browser is no longer supported. Please, upgrade your browser.
Settings
HZNP Horizon Pharma plc daily Stock Chart
HZNP [NASD]
Horizon Pharma plc
Index- P/E- EPS (ttm)-0.69 Insider Own0.80% Shs Outstand177.34M Perf Week-3.76%
Market Cap4.76B Forward P/E13.27 EPS next Y2.02 Insider Trans-23.15% Shs Float177.34M Perf Month26.37%
Income-111.60M PEG- EPS next Q0.12 Inst Own84.20% Short Float2.94% Perf Quarter45.71%
Sales1.21B P/S3.94 EPS this Y77.00% Inst Trans-3.33% Short Ratio2.66 Perf Half Y42.39%
Book/sh6.33 P/B4.24 EPS next Y14.43% ROA-1.80% Target Price30.00 Perf Year84.34%
Cash/sh5.41 P/C4.96 EPS next 5Y16.40% ROE-8.00% 52W Range12.55 - 29.44 Perf YTD37.36%
Dividend- P/FCF25.09 EPS past 5Y22.10% ROI0.30% 52W High-8.83% Beta1.15
Dividend %- Quick Ratio2.00 Sales past 5Y74.80% Gross Margin65.00% 52W Low113.85% ATR1.20
Employees1000 Current Ratio2.00 Sales Q/Q29.60% Oper. Margin0.20% RSI (14)56.70 Volatility3.83% 5.05%
OptionableYes Debt/Eq1.80 EPS Q/Q146.00% Profit Margin-6.10% Rel Volume1.16 Prev Close27.91
ShortableYes LT Debt/Eq1.80 EarningsFeb 27 BMO Payout- Avg Volume1.96M Price26.84
Recom2.10 SMA202.74% SMA5013.33% SMA20032.72% Volume2,277,665 Change-3.83%
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Jul-11-16Upgrade Morgan Stanley Underweight → Equal-Weight $24
Jun-06-16Initiated Goldman Buy $24
May-10-16Reiterated Mizuho Buy $25 → $24
May-03-16Reiterated Mizuho Buy $34 → $25
Jan-19-16Resumed Jefferies Buy $31
Mar-21-19 01:07PM  Which Pharmaceutical Stocks Are Outperforming All Other Stocks? Investor's Business Daily
12:06AM  Edited Transcript of HZNP earnings conference call or presentation 27-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
Mar-18-19 08:00AM  Horizon Pharma plc Wins PR News CSR Award for Partnership with Perspectives Math and Science Academy Business Wire
Mar-11-19 04:30PM  Horizon Pharma plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Mar-08-19 04:35PM  Why This Top-Ranked Pharma Grabbed An Upgrade Despite DOJ Probe Investor's Business Daily
Mar-06-19 10:00PM  Horizon Pharma plc Announces Pricing of Public Offering of Ordinary Shares Business Wire -6.39%
04:09PM  No. 1 Pharma Stock Dives As DOJ Investigates Potential Kickbacks Investor's Business Daily
07:41AM  Dow Jones Futures: Nio, Qutoutiao IPOs Lead 5 Key Stocks Moving Investor's Business Daily
07:39AM  The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split Benzinga
Mar-05-19 08:10AM  Analysis: Positioning to Benefit within The Goodyear Tire & Rubber, Cars, Tutor Perini, CVS Health, VMware, and Horizon Pharma Public Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-04-19 04:10PM  Horizon Pharma plc Announces Proposed Public Offering of Ordinary Shares Business Wire
09:00AM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Mar-02-19 10:00AM  Celebrating the Greatness of Individual Traders TheStreet.com
Mar-01-19 05:50PM  Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
09:30AM  Company News For Mar 1, 2019 Zacks
08:50AM  The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis Benzinga
08:00AM  Why These Pharma ETFs Rallied on Thursday Zacks
07:37AM  3 Big Stock Charts for Friday: Eli Lilly, Centene and LKQ Corporation InvestorPlace
Feb-28-19 04:32PM  Why Monster Beverage, Horizon Pharma, and Guardant Health Jumped Today Motley Fool +32.77%
04:26PM  No. 1 Pharma Skyrockets To 4-Year High On Bullish Results In Eye Disease Investor's Business Daily
02:30PM  Monster Beverage Leads Nasdaq 100; J&J, Coca-Cola, Walmart Prop Up Dow Jones Investor's Business Daily
12:00PM  Why Horizon Pharma Is Surging Today Motley Fool
11:12AM  Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat Zacks
11:10AM  Horizon Pharma Stock Goes Vertical After Positive Eye Disease Drug Results TheStreet.com
07:17AM  UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment MarketWatch
07:00AM  Horizon Pharma plc Announces Phase 3 Confirmatory Trial Evaluating Teprotumumab (OPTIC) for the Treatment of Active Thyroid Eye Disease (TED) Met Primary and All Secondary Endpoints Business Wire
Feb-27-19 04:22PM  IBD 50 Pharma Stock Pops On Quarterly Beat; Guidance In Line Investor's Business Daily
11:50AM  Horizon Pharma PLC (HZNP) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Horizon Pharma plc Reports Record Fourth-Quarter and Full-Year 2018 Net Sales Driven by Orphan and Rheumatology Segment; Announces Full-Year 2019 Guidance Business Wire
Feb-25-19 08:00AM  Horizon Pharma plc to Participate in Cowen and Company 39th Annual Health Care Conference Business Wire
Feb-20-19 10:31AM  Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Feb-07-19 10:42AM  Q4 Earnings: Veeva, Splunk, Ciena Among 17 Stocks Expecting 52%-2,200% Growth Investor's Business Daily
Feb-05-19 04:36PM  This Highly Rated Pharma Stock Just Broke Out Ahead Of Earnings Investor's Business Daily
02:33PM  With Boeing Boost, Dow Jones Index Leads Stock Indexes Investor's Business Daily
01:30PM  Nasdaq Today: Bullish Breakouts For Etsy, Horizon Pharma Investor's Business Daily
Feb-04-19 07:30AM  Report: Developing Opportunities within Southern, Horizon Pharma Public, Celestica, RCI Hospitality, Bluerock Residential Growth REIT, and Tilly's Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-31-19 04:19PM  IBD Stock Of The Day: Top-Rated Pharma Stock Approaches Breakout Investor's Business Daily
Jan-29-19 08:00AM  Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2018 Financial Results and Host Webcast on Feb. 27, 2019 Business Wire
Jan-16-19 12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
Jan-15-19 08:37AM  Do Options Traders Know Something About Horizon Pharma (HZNP) Stock We Don't? Zacks
Jan-14-19 01:29PM  Blue Chips Pare Losses; JPMorgan, Goldman Sachs Lead Dow Jones Investor's Business Daily
Jan-10-19 12:08PM  Horizon Pharma Surged On Earnings But Came Back Down With The Market Investor's Business Daily Video
Jan-08-19 02:02PM  IBD 50 Stocks To Watch: Horizon Pharma Setting Up New Buy Point Investor's Business Daily
02:01PM  IBD 50 Growth Stocks To Watch Investor's Business Daily
Jan-04-19 01:31PM  Big Gains on the Horizon for This Pharma Stock, History Says Schaeffer's Investment Research
Jan-03-19 08:00AM  Horizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout Business Wire
Jan-02-19 04:28PM  Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy Zacks
Dec-29-18 08:00AM  3 Top Mid-Cap Stocks to Buy Right Now Motley Fool
Dec-28-18 08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-27-18 02:46PM  S&P 500 Today Down Sharply; This Sign Will Tell A Lot About Current Stock Market Investor's Business Daily
08:00AM  Horizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns Business Wire
Dec-23-18 09:01AM  Challenges Facing Health Care Stocks in 2019 Investopedia
Dec-21-18 12:15PM  Why Horizon Pharma Public Limited Companys (NASDAQ:HZNP) CEO Pay Matters To You Simply Wall St.
Dec-17-18 05:20PM  Horizon Pharma, Inc. -- Moody's affirms Horizon Pharma's B2 CFR; revises outlook to stable from negative Moody's
08:00AM  Horizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-14-18 10:33PM  Do Hedge Funds Love Horizon Pharma Public Limited Company (HZNP)? Insider Monkey
Nov-29-18 07:40AM  Investor Expectations to Drive Momentum within Mammoth Energy Services, Horizon Pharma Public, SBA Communications, International Flavors & Fragrances, WillScot, and Teekay Tankers Discovering Underlying Factors of Influence GlobeNewswire
Nov-19-18 03:52PM  Edited Transcript of HZNP earnings conference call or presentation 7-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-18 01:45PM  Top Stocks: IBD Screens Uncover Emerging Leaders Before Big Moves Investor's Business Daily
08:00AM  Horizon Pharma plc to Participate in Upcoming Conferences Business Wire
Nov-15-18 02:19PM  No. 1 Pharma Sees $1.5 Billion From Two Drugs And It's Not Stopping There Investor's Business Daily
10:12AM  Stocks Volatile Early; These 2 Dow Stocks Reported Earnings Investor's Business Daily
Nov-12-18 04:15PM  IBD Stock Of The Day Nears Buy Point As It Outperforms Big Pharma Rivals Investor's Business Daily
Nov-08-18 11:13AM  Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise Zacks
07:00AM  Why Horizon Pharma PLC Stock Is Spiking Today Motley Fool
Nov-07-18 04:11PM  This Pharma Stock Broke Out In Bullish Fashion Here's Why Investor's Business Daily +15.97%
09:20AM  Horizon Pharma (HZNP) Tops Q3 Earnings and Revenue Estimates Zacks
08:15AM  Horizon Pharma: 3Q Earnings Snapshot Associated Press
07:00AM  Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance Business Wire
Nov-02-18 09:30AM  The Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace Business Wire
Oct-31-18 10:32AM  Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Oct-29-18 05:57PM  Horizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting Business Wire
08:00AM  Today's Research Reports on Trending Tickers: TherapeuticsMD and Horizon Pharma Public ACCESSWIRE
Oct-25-18 01:00PM  Horizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity Business Wire
08:00AM  Horizon Pharma plc to Participate in Investor Conferences in November Business Wire
Oct-22-18 08:00AM  Horizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting Business Wire
Oct-19-18 08:50AM  Market Trends Toward New Normal in Endeavour Silver, Triton International, Resonant, Radware, Horizon Pharma Public, and Ensco plc Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Oct-18-18 09:16AM  FORTUNE and Great Place to Work® Name Horizon Pharma plc to 2018 Best Small & Medium Workplaces for Third Consecutive Year Business Wire
Oct-10-18 08:00AM  Today's Research Reports on Trending Tickers: Agile Therapeutics and Horizon Pharma ACCESSWIRE
08:00AM  Horizon Pharma plc to Release Third-Quarter 2018 Financial Results and Host Webcast on Nov. 7, 2018 Business Wire
Oct-04-18 09:02AM  Horizon Pharma plc Announces Presentation of Data From 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab Business Wire
Sep-27-18 11:00AM  The North American Pediatric Renal Trials and Collaborative Studies and Horizon Pharma plc Announce New Long-Term Cystinosis Registry Business Wire
08:00AM  Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout Business Wire
Sep-25-18 08:00AM  Horizon Pharma plc to Present 48-Week Follow-Up Analysis of the Teprotumumab Phase 2 Trial at the Annual Meeting of the American Thyroid Association Business Wire
Sep-07-18 09:30AM  Horizon Pharma (HZNP) Down 1.9% Since Last Earnings Report: Can It Rebound? Zacks
Sep-05-18 05:34PM  Horizon Pharma Completes Enrollment in Eye Disease Study Zacks
Sep-04-18 08:00AM  Horizon Pharma plc to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference Business Wire
07:00AM  Horizon Pharma plc Completes Enrollment of Confirmatory Phase 3 Trial of Teprotumumab Ahead of Schedule Business Wire
Aug-27-18 05:44AM  Edited Transcript of HZNP earnings conference call or presentation 8-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-24-18 08:35AM  These 3 Value Stocks Are Absurdly Cheap Right Now Motley Fool
Aug-22-18 06:22AM  Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition Zacks
Aug-21-18 08:10AM  Investor Expectations to Drive Momentum within Materialise NV, Southern First Bancshares, Ensco plc, Corbus Pharmaceuticals, TCP Capital, and Horizon Pharma Public Discovering Underlying Factors of Influence GlobeNewswire
Aug-09-18 09:17AM  Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise Zacks
Aug-08-18 03:51PM  Here's Why Horizon Pharma PLC Rose by Double Digits Today Motley Fool +10.79%
08:50AM  Horizon Pharma (HZNP) Tops Q2 Earnings and Revenue Estimates Zacks
07:45AM  Horizon Pharma: 2Q Earnings Snapshot Associated Press
07:00AM  Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases Business Wire
Aug-06-18 11:21AM  Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings? Zacks
Jul-25-18 09:00AM  PEOPLE and Great Place to Work® Name Horizon Pharma plc to 2018 50 Companies That Care List Business Wire
Jul-23-18 03:05PM  7 Healthcare Stocks That Are Coming to Life InvestorPlace
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Its primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. Horizon Pharma Public Limited Company has collaboration agreements with Alliance for Lupus Research to evaluate RAYOS/LODOTRA on the fatigue experienced by systemic lupus erythematosus patients; Syneos Health, Inc. in connection with its Phase III confirmatory trial to evaluate teprotumumab for the treatment of thyroid eye disease; and HemoShear Therapeutics, LLC to discover and develop therapeutics for gout. The company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOFeb 25Sale21.2110,080213,77128,867Feb 25 07:03 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOFeb 05Sale23.158,835204,55928,867Feb 05 04:41 PM
McHugh Miles WSr VP & Princ. Acctg OfficerJan 22Option Exercise12.1916,406199,98999,140Jan 23 04:47 PM
McHugh Miles WSr VP & Princ. Acctg OfficerDec 26Option Exercise12.1916,406199,98979,346Dec 28 04:50 PM
Walbert Timothy PChairman, President and CEONov 19Option Exercise4.3249,801214,959595,871Nov 21 04:41 PM
Walbert Timothy PChairman, President and CEONov 14Option Exercise7.12408,3472,906,049954,417Nov 16 07:11 PM
Walbert Timothy PChairman, President and CEONov 14Sale21.54408,3478,795,794546,070Nov 16 07:11 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOAug 16Sale20.639,904204,36128,767Aug 20 04:29 PM
Beeler Brian KEVP, General CounselJun 08Sale17.5815,433271,24979,530Jun 12 05:00 PM
Walbert Timothy PChairman, President and CEOJun 01Option Exercise10.4383,353869,372629,423Jun 05 04:13 PM
Walbert Timothy PChairman, President and CEOJun 01Sale16.1783,3531,348,218546,070Jun 05 04:13 PM
Beeler Brian KEVP, General CounselMay 25Option Exercise2.4048,000115,200110,524May 30 04:49 PM
Beeler Brian KEVP, General CounselMay 25Sale16.1117,931288,86892,593May 30 04:49 PM